30
Participants
Start Date
August 31, 2013
Primary Completion Date
July 31, 2015
Study Completion Date
August 31, 2016
GC4419
GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
University of Rochester Medical Center, Rochester
Allegheny General Hospital, Pittsburgh
St. Luke's Cancer Center, Easton
Wake Forest Baptist Health, Winston-Salem
Lakeland Regional Cancer Center, Lakeland
Summa Health System- Cooper Cancer Center, Akron
University of Iowa, Iowa City
Washington University School of Medicine, St Louis
University of Nebraska Medical Center, Omaha
Cancer Care Northwest, Spokane
Lead Sponsor
Galera Therapeutics, Inc.
INDUSTRY